Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
The Lancet. Oncology|December 17, 2022
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trialRoberto Mina, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survivalAntonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
The Lancet. Oncology|June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma NetworkHeinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
Journal of Cancer Research and Clinical Oncology|April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysisChiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.
Haematologica|March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trialsSara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Nature Medicine|April 6, 2026
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trialFrancesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos, et al.
Haematologica|March 19, 2026
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasoneCarmine Liberatore, Alfonso Piciocchi, Donatella Vincelli, et al.
British Journal of Haematology|July 17, 2021
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignanciesFrancesco Passamonti, Alessandra Romano, Marco Salvini, et al.
Hematological Oncology|October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohortMichele Merli, Isacco Ferrarini, Francesco Merli, et al.
Pageof 8